Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status
Ann Oncol
.
2017 Mar 1;28(3):665-666.
doi: 10.1093/annonc/mdw657.
Authors
G Roviello
1
,
C Pacifico
2
,
K Polom
3
,
F Roviello
3
,
D Generali
4
5
Affiliations
1
Unit of Medical Oncology, Department of Oncology, Ospedale San Donato, Arezzo.
2
Department of Medical, Surgical and Neurological Sciences, University Hospital of Siena, Radiotherapy Unit, Siena.
3
Unit of General and Minimally Invasive Surgery, Surgery and Neuroscience; University of Siena, Siena.
4
Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona, Cremona.
5
Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
PMID:
27993812
DOI:
10.1093/annonc/mdw657
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized
Esophagogastric Junction*
Humans
Neoplasms
Ramucirumab
Stomach Neoplasms
Substances
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized